Psyence Biomed's Chief of Global Impact to Speak at Psychedelic Science 2025

Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, will be a featured speaker at Psychedelic Science 2025 (PS2025), the largest international conference dedicated to psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), the event is scheduled for June 16-20, 2025, in Denver, Colorado. Gifford will participate in a panel titled 'We are the Guardrails: Profit with Purpose,' focusing on business ethics in the psychedelic industry.

As Chief of Global Impact for Psyence Biomed, Gifford plays a pivotal role in bridging the gap between research, regulation, and patient care. Psyence Biomed is notable for being the first Nasdaq-listed biopharmaceutical company to focus on developing nature-derived (non-synthetic) psilocybin medicine for FDA approval. This participation underscores the company's commitment to ethical business practices and its leadership in the psychedelic therapeutics sector.

The conference represents a significant opportunity for Psyence Biomed to showcase its dedication to addressing unmet mental health needs, particularly in palliative care, through evidence-based, nature-derived psychedelic treatments. The selection of Gifford as a speaker at PS2025 highlights the growing recognition of Psyence Biomed's contributions to the field and the importance of integrating ethical considerations into the burgeoning psychedelic industry.

For further details on Psyence Biomed's initiatives and its participation in Psychedelic Science 2025, interested parties can view the full press release here.